The utility of ctDNA, particularly CSF ctDNA, as a complementary diagnostic tool in neuro-oncology is supported, with a promising performance of ctDNA analysis in patients with diffuse gliomas as a liquid biopsy strategy.
Abstract
Abstract Introduction Accurate molecular characterization of gliomas is essential for determining prognosis and guiding therapeutic decisions. In recent years, liquid biopsy for analysis of circulating tumor DNA (ctDNA) in blood or cerebrospinal fluid (CSF) has emerged as a promising, minimally invasive alternative. This study evaluates the existing literature on the utility of ctDNA detection in CSF and blood in patients with gliomas, with the goal of assessing its ability to identify mutations concordant with those detected in tumor tissue. Methods A systematic search was conducted up to April 30, 2026, to identify cohorts that evaluated the effectiveness of ctDNA-based liquid biopsies for gliomas. The primary assessed outcomes were the sensitivity and specificity of the liquid biopsies using CSF or plasma. A pooled sensitivity analysis was performed, as well as summary receiver operating characteristic (SROC) curves. Results Twenty-eight studies met the inclusion criteria, encompassing 613 patients. Meta-analysis of diagnostic performance revealed improved biomarker performance for CSF (Area under the curve [AUC] 0.95) ctDNA. Pooled sensitivity for ctDNA detection in patients with gliomas was higher in CSF 0.79 (95% CI, 0.69-0.85) than in plasma 0.29 (95% CI, 0.15-0.47), P < .0001. Conclusion The literature demonstrates a promising performance of ctDNA analysis in patients with diffuse gliomas as a liquid biopsy strategy. CSF ctDNA analysis exhibited superior sensitivity compared to plasma ctDNA. This meta-analysis supports the utility of ctDNA, particularly CSF ctDNA, as a complementary diagnostic tool in neuro-oncology.
The feasibility of integrating multimodal liquid biopsy and volumetric imaging into routine neurosurgical practice for GBM is demonstrated, and the proposed workflow provides a reproducible foundation for larger studies aimed at advancing clinical implementation of liquid biopsy strategies.
M. Chiapponi, Fabiola Cappella, Laura Andreacchio et al.· Neuro-Oncology Practice· 0 citations
Background Spinal glioblastoma (GBM) is an exceptionally rare entity and poses significant diagnostic challenges due to a substantial risk of neurological morbidity with surgical biopsy. Tissue-based analyses are frequently limited by sampling constraints and tumor heterogeneity. Conventional diagnostic modalities, inc...
Carlen A. Yuen, David O. Kamson, Chang-Rui Xiao et al.· Frontiers in Oncology· 0 citations
Despite low cfDNA abundance, CSF NGS and LPWGS provide informative data across neuro-oncologic indications and further work is underway to optimize the assays for low input CSF cfDNA.
C. Riviere-Cazaux, Rahul Kumar, Julian S. Rechberger et al.· Journal of Neuro-Oncology· 0 citations
LCx using combined DNA and RNA NGS testing of CSF is a reliable approach that yields potentially practice-changing clinical information, and suggests that LBx using combined DNA and RNA NGS testing of CSF is a reliable approach that yields potentially practice-changing clinical information.
M. Albitar, Ahmad Charifa, Sally Agersborg et al.· The journal of liquid biopsy· 0 citations
Glioblastoma CNS WHO Grade 4 (GBM) is associated with poor prognosis and high recurrence rates despite the current therapeutic approaches. Conventional imaging, in particular Magnetic Resonance Imaging (MRI), is primarily used during follow-up to detect tumor recurrence but has limited ability to distinguish recurr...
R. Muhtadi, Christian D. Diehl, N. Schmid et al.· Frontiers in Oncology· 0 citations